Brae­burn Phar­ma files for $150M IPO; Tiziana in-li­cens­es Novim­mune an­ti­body

• Brae­burn Phar­ma­ceu­ti­cals, which mar­kets and de­vel­ops treat­ments for opi­oid ad­dic­tion, has filed for a $150 mil­lion IPO. The of­fer­ing notes that Ap­ple Tree Part­ners …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER